medicina61巻1号

2024年01月発行

特集 その知見は臨床を変える?—エキスパートが解説! 内科における最新論文 膠原病と類縁疾患

Ⅰ型インターフェロンから紐解く全身性エリテマトーデス（SLE）治療

著者： 髙橋達郎¹ 岩本太郎¹ 古田俊介¹

所属機関： ¹千葉大学医学部附属病院アレルギー・膠原病内科

ページ範囲：P.136 - P.142

Point
◎全身性エリテマトーデス（SLE）は若年女性に好発する多臓器に障害をもたらす自己免疫疾患である．
◎SLE患者の短期予後は改善したものの，長期予後は一般集団と比較し依然として悪い．
◎SLEの発症と病態形成にはⅠ型インターフェロン（IFN）経路が大きな役割を果たしている．
◎既存のⅠ型IFN経路を標的とした治療薬は有用だが，治療抵抗例も多く，新規薬剤の開発が望まれる．
◎治療中のSLE患者は帯状疱疹の発症ハイリスク群であり，ワクチンによる予防が推奨される．

参考文献

1）Bultink IEM, et al：Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology（Oxford）60：207-216, 2021 PMID 32653901

2）Furie R, et al：A phase Ⅲ, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63：3918-3930, 2011 PMID 22127708

3）Morand E, et al：Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382：211-221, 2022 PMID 31851795

4）Merrill JT, et al：Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus；The randomized, double-blind, phase Ⅱ/Ⅲ systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62：222-233, 2010 PMID 20039413

5）Rovin BH et al：Efficacy and safety of rituximab in patients with active proliferative lupus nephritis；The lupus nephritis assessment with rituximab study. Arthritis Rheum 64：1215-1226, 2012 PMID 22231479

6）Munroe ME, et al：Altered type Ⅱ interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis 75：2014-2021, 2016 PMID 27088255

7）Woo JMP, et al：The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous. J Intern Med 291：755-778, 2022 PMID 35143075

8）Tomofuji Y, et al：Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese. Ann Rheum Dis 80：1575-1583, 2021 PMID 34426398

9）Yin X, et al：Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus. Ann Rheum Dis 80：632-640, 2021 PMID 33272962

10）Wang YF, et al：Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups. Nature Communications 12：772, 2021 PMID 33536424

11）Rahman A, et al：Systemic lupus erythematosus. N Engl J Med 358：929-939, 2008 PMID 18305268

12）Yu Y, Su K：Neutrophil extracellular traps and systemic lupus erythematosus. J Clin Cell Immunol 4：139, 2013 PMID 24244889

13）Miyachi K, et al：Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients；A retrospective longitudinal analysis. Arthritis Res Ther 25：26, 2023 PMID 36803843

14）Niewold TB, et al：High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8：492-502, 2007 PMID 17581626

15）Niewold TB, et al：Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum 58：2113-2119, 2008 PMID 18576315

16）Oke V, et al：High levels of circulating interferons type Ⅰ, type Ⅱ and type Ⅲ associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther 21：107, 2019 PMID 31036046

17）Iwamoto T, et al：High Systemic type I interferon activity is associated with active class Ⅲ/Ⅳ lupus nephritis. J Rheumatol 49：388-397, 2022 PMID 34782453

18）Dörner T：Therapy：hydroxychloroquine in SLE；Old drug, new perspectives. Nat Rev Rheumatol 6：10-11, 2010 PMID 20046202

antibody litifilimab for systemic lupus erythematosus. N Engl J Med 387：894-904, 2022 PMID 36069871

20）Morand E, et al：Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus；A phase Ⅱ, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 75：242-252, 2023 PMID 36369798

21）Merrill JT, et al：Efficacy and safety of ABBV-599 high dose（elsubrutinib 60 mg and upadacitinib 30 mg）and upadacitinib monotherapy for the treatment of systemic lupus erythematosus；A phase 2, double-blind, placebo-controlled, trial. Ann Rheum Dis 82：91-92, 2023

22）Blomberg S, et al：Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 48：2524-2532, 2003 PMID 13130472

23）Psarras A, et al：Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nat Commun 11：6149, 2020 PMID 33262343

24）Zhou Z, et al：Phenotypic and functional alterations of pDCs in lupus-prone mice. Sci Rep 6：20373, 2016 PMID 26879679

25）Psarras A, et al：Emerging concepts of type Ⅰ interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol 18：575-590, 2022 PMID 36097207

26）Bass AR, et al：2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res（Hoboken）75：449-464, 2023 PMID 36597813